| Prev Close | 270.28 |
| Open | 270.25 |
| Day Low/High | 268.32 / 270.68 |
| 52 Wk Low/High | 223.25 / 374.99 |
| Volume | 33.47K |
Biogen Inc. (BIIB)
268.77
1.50
0.56
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 153.88B |
| Market Cap | 42.14B |
| P/E Ratio | 9.03 |
| Div & Yield | N.A. (N.A) |
Real Money Post Industrial Average Bests Most Major Indexes in 2020
As we enter the new year, there's little time to reflect on RMPIA's strong performance. Now, it's all eyes on the 12 months ahead of us.
Real Money Post Industrial Average Climbs 9.5% Over November
The RMPIA also tops other indexes for year, shooting ahead 29%.
Bearish Bets: 2 Biotech Stocks You Should Consider Shorting This Week
These names are displaying both technical and quantitative deterioration.
Real Money Post Industrial Average Rises 21% Year to Date
The average declined in October, but it was less than that hit took by the major indexes.
The Market Is Shrugging Off the Political News
And that is helping to create fear of missing out.
'Inside Day', Electoral Risk, Banking Stocks, Stimulus Immediately Needed
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
Immatics Is a Bit Boy Who Cried Wolf
This is the type of chart that will grab the attention of momentum traders.
Veeva and RedHill: 2 Stocks to Consider as They Team Up to Battle Covid-19
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
2 Biotech Stocks to Buy on Solid Q2 Results
Covid-19 has had a big impact on this sector, but these names have strong catalysts going into the next quarter.
Real Money Post Industrial Average Again Outperformed, but Watch Valuations
The Real Money Post Industrial Average is up nearly 11% so far this quarter, beating all major indices, but valuations are looking stretched.
Markets at a Crossroads, Trump on Health Crisis, China to Shut Houston Consulate
The markets are really in the hands of Washington right now, and Washington is in the hands of the virus.
Real Money Post Industrial Average Outperforms, Despite Outbreak
The RMPIA rebounded more than 22% in the June quarter to finish up 7.8% at the 2020 half mark.
I Did a Double Take When I Saw Alcoa Atop the Top 10 Trending Stocks
Let's look at the chart and see how I'd trade AA.
Biogen Jumps on Alzheimer's Drug News, But What Do the Charts Say?
Let's take a close look at BIIB and arrive at a strategy for the shares.
7 Drug Stocks With the Right Medicine for Investors
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
Jim Cramer: A Recession Might Be Good Medicine Right Now
A bear market, if it gets us all to slow down, may be necessary to slow the coronavirus' spread -- but this doesn't mean I'm giving up. To the contrary.
Sangamo Therapeutics Shows Promise
Let's check out the charts of SGMO and come up with a trading strategy.
Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon
It's no secret that the Fed would like to get out of the short-term repo business.
4 Favorite Biotech Stock Picks for 2020
The Medical Technology Stock Letter's top pick rose 357% in 2019.
Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average
Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.
Jim Cramer: Think Owning Tech Is Hard? Look at This Post-Impeachment Record
A lot of the names that fell hard after the Clinton impeachment have been record earners since then.
Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not
We're seeing lots of companies snapping up their peers, and the market is applauding.
